187 related articles for article (PubMed ID: 34031486)
1. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Lehman CE; Khalil AA; Axelrod MJ; Dougherty MI; Schoeff SS; Taniguchi LE; Mendez RE; David AP; McGarey PO; Hubbard MA; Donaldson L; Frierson HF; Stelow EB; Bekiranov S; Wulfkuhle JD; Petricoin EF; Gioeli DG; Jameson MJ
Laryngoscope; 2020 Jun; 130(6):1470-1478. PubMed ID: 31433065
[TBL] [Abstract][Full Text] [Related]
4. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
6. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Hehlgans S; Eke I; Cordes N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702
[TBL] [Abstract][Full Text] [Related]
7. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
8. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of focal adhesion kinase/paxillin axis by caffeic acid phenethyl ester restrains aggressive behaviors of head and neck squamous cell carcinoma in vitro.
Yu HJ; Shin JA; Cho SD
Arch Oral Biol; 2023 Feb; 146():105611. PubMed ID: 36577313
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
El Sayed I; Helmy MW; El-Abhar HS
Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
[TBL] [Abstract][Full Text] [Related]
11. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
[TBL] [Abstract][Full Text] [Related]
13. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
von Mässenhausen A; Sanders C; Brägelmann J; Konantz M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Lengerke C; Perner S
Int J Cancer; 2016 Nov; 139(10):2359-69. PubMed ID: 27434411
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Eke I; Cordes N
Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
[TBL] [Abstract][Full Text] [Related]
16. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
Bauman JE; Duvvuri U; Gooding WE; Rath TJ; Gross ND; Song J; Jimeno A; Yarbrough WG; Johnson FM; Wang L; Chiosea S; Sen M; Kass J; Johnson JT; Ferris RL; Kim S; Hirsch FR; Ellison K; Flaherty JT; Mills GB; Grandis JR
JCI Insight; 2017 Mar; 2(6):e90449. PubMed ID: 28352657
[No Abstract] [Full Text] [Related]
17. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
18. Effects of S‑adenosyl‑L‑methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms.
Mosca L; Minopoli M; Pagano M; Vitiello F; Carriero MV; Cacciapuoti G; Porcelli M
Int J Oncol; 2020 May; 56(5):1212-1224. PubMed ID: 32319579
[TBL] [Abstract][Full Text] [Related]
19. p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.
Srivastava K; Pickard A; McDade S; McCance DJ
Oncotarget; 2017 Mar; 8(10):16202-16219. PubMed ID: 26001294
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
